NASDAQ: ALXO

ALX Oncology Holdings Inc.

Healthcare | Biotechnology

No licensed closing price on file for ALXO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

ALX Oncology Holdings Inc. (NASDAQ: ALXO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 05:22 UTC.

What ALX Oncology Holdings Inc. does

ALX Oncology is a clinical-stage biotechnology company developing novel therapies for cancer treatment. The company's lead product candidate, evorpacept, is a CD47 blocker designed to help the immune system recognize and attack cancer cells while avoiding the blood cell damage caused by competing CD47 blocking approaches. Evorpacept is being evaluated in clinical trials in combination with other anti-cancer agents, including in patients with metastatic HER2-positive breast cancer and gastric cancer.

Summarized from ALX Oncology Holdings Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-30
Return on equity	-10.64%
Debt/equity	0.07

Charts

Charts are in the appInteractive charts for ALXO are available in Oxford Ledge.
Open ALXO in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-08-18

2026-08-18CHIEF EXECUTIVE OFFICERSale-2,230$4.3K
2026-08-18SVP, FINANCE AND CAOSale-573$1.1K
2026-07-06SVP, FINANCE AND CAOSale-1,404$2.9K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

RA CAPITAL MANAGEMENT, L.P.13,011,849$26.93M0.0%
venBio Partners LLC12,884,638$26.67M0.0%
BlackRock, Inc.7,399,530$15.32M+1552.4%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-08-12Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-01-22Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-11-07Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Yahoo2026-08-11
ALX Oncology GAAP EPS of -$0.13
Seeking Alpha Markets2026-08-06
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
globenewswire.com2026-04-17

Questions this page answers

What does ALX Oncology Holdings Inc. do?

ALX Oncology is a clinical-stage biotechnology company developing novel therapies for cancer treatment.

When did ALXO last file with the SEC?

ALX Oncology Holdings Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-30. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 05:22 UTC. This page is also available as JSON at /api/data?ticker=ALXO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ALXO and 5,000+ tickers.

Create a free account — keep ALXO

For your agent

GET /api/data?ticker=ALXO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt